Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Google’s ( GOOGL) anti-aging company Calico released disappointing trial results of its first ever drug.

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...

Announcing a new publication for Acta Materia Medica journal. Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the develo ...

A study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, ...

A clinical trial evaluating the drug fosigotifator in patients with amyotrophic lateral sclerosis has failed to meet its primary endpoint, according to topline results from the Healey ALS platform ...